Angola vs South Korea: The number of people with susceptibility test result for rifampicin
Angola
10,250
in 2021
South Korea
9,284
in 2021
Angola rank
21st
South Korea rank
22nd
The number of people with susceptibility test result for rifampicin over time
- Angola
- South Korea
How they compare
Angola currently reports 10,250 against 9,284 in South Korea, a difference of 966.
That makes Angola's figure about 1.1 times South Korea's.
The two have swapped places 3 times across 5 shared years of data; in 2017 it was South Korea ahead.
Angola ranks 21st and South Korea ranks 22nd of 155 countries.
South Korea has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Angola | South Korea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 9,969 | 13,475 | 3,506 | South Korea |
| 2020s | 5,672 | 9,936 | 4,264 | South Korea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Angola or South Korea?
- Angola, at 10,250 against 9,284 in South Korea as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Angola and South Korea?
- 966, with Angola ahead.
- How many years of comparable data are there for Angola and South Korea?
- 5 years are reported by both, from 2017 to 2021.
- How do Angola and South Korea rank globally for the number of people with susceptibility test result for rifampicin?
- Angola ranks 21st and South Korea ranks 22nd of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.